View Financial HealthRBC Bioscience 배당 및 자사주 매입배당 기준 점검 3/6RBC Bioscience 수익으로 충분히 충당되는 현재 수익률 1.58% 보유한 배당금 지급 회사입니다.핵심 정보1.6%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률-31.3%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향22%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Sep 25Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 02 October 2025. Payment date: 31 October 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.7%).Upcoming Dividend • Sep 12Upcoming dividend of NT$0.56 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 18 October 2024. Payout ratio is on the higher end at 75%, however this is supported by cash flows. Trailing yield: 5.6%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (1.2%).Upcoming Dividend • Jul 29Upcoming dividend of NT$0.44 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 30 August 2024. Payout ratio is on the higher end at 89%, and the cash payout ratio is above 100%. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (1.3%).Upcoming Dividend • Jul 06Upcoming dividend of NT$1.12 per share at 6.2% yieldEligible shareholders must have bought the stock before 13 July 2023. Payment date: 11 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 6.2%. Within top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.0%).모든 업데이트 보기Recent updatesReported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$1.65 (vs NT$1.51 in FY 2024)Full year 2025 results: EPS: NT$1.65 (up from NT$1.51 in FY 2024). Revenue: NT$219.7m (up 7.0% from FY 2024). Net income: NT$23.5m (up 9.2% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Apr 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 9.1% to NT$17.90. The fair value is estimated to be NT$14.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.공시 • Apr 01RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$218.6m market cap, or US$6.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Jan 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$212.8m market cap, or US$6.72m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Buy Or Sell Opportunity • Dec 16Now 21% overvaluedOver the last 90 days, the stock has fallen 7.6% to NT$17.00. The fair value is estimated to be NT$14.10, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.Buy Or Sell Opportunity • Nov 26Now 21% overvaluedOver the last 90 days, the stock has fallen 5.7% to NT$17.30. The fair value is estimated to be NT$14.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.Buy Or Sell Opportunity • Nov 11Now 21% overvaluedOver the last 90 days, the stock has fallen 2.0% to NT$17.55. The fair value is estimated to be NT$14.53, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.Upcoming Dividend • Sep 25Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 02 October 2025. Payment date: 31 October 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.7%).공시 • Mar 31RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$260.2m market cap, or US$7.90m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Dec 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$254.3m market cap, or US$7.75m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.1% average weekly change).New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$267.3m market cap, or US$8.32m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.4% average weekly change).Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$22.70, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total returns to shareholders of 59% over the past year.Upcoming Dividend • Sep 12Upcoming dividend of NT$0.56 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 18 October 2024. Payout ratio is on the higher end at 75%, however this is supported by cash flows. Trailing yield: 5.6%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (1.2%).Upcoming Dividend • Jul 29Upcoming dividend of NT$0.44 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 30 August 2024. Payout ratio is on the higher end at 89%, and the cash payout ratio is above 100%. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (1.3%).Reported Earnings • Apr 25Full year 2023 earnings released: EPS: NT$0.50 (vs NT$0.29 in FY 2022)Full year 2023 results: EPS: NT$0.50 (up from NT$0.29 in FY 2022). Revenue: NT$172.5m (flat on FY 2022). Net income: NT$6.43m (up 70% from FY 2022). Profit margin: 3.7% (up from 2.2% in FY 2022).공시 • Apr 12RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024.New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.3x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (NT$209.6m market cap, or US$6.63m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change).Buy Or Sell Opportunity • Feb 20Now 23% undervaluedOver the last 90 days, the stock has risen 5.3% to NT$15.90. The fair value is estimated to be NT$20.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 4.8% to NT$15.25. The fair value is estimated to be NT$19.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Buying Opportunity • Jan 16Now 21% undervaluedOver the last 90 days, the stock is up 3.8%. The fair value is estimated to be NT$19.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Buying Opportunity • Nov 29Now 20% undervaluedOver the last 90 days, the stock is up 3.7%. The fair value is estimated to be NT$19.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Upcoming Dividend • Jul 06Upcoming dividend of NT$1.12 per share at 6.2% yieldEligible shareholders must have bought the stock before 13 July 2023. Payment date: 11 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 6.2%. Within top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.0%).Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$21.25, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 40% over the past year.Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 26%After last week's 26% share price gain to NT$17.75, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 49% over the past year.Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$17.70, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total loss to shareholders of 43% over the past year.Valuation Update With 7 Day Price Move • Apr 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$47.15, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 35x in the Life Sciences industry in Asia.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 6848 10년 미만 동안 배당금을 지급해 왔으며 이 기간 동안 지급액은 휘발성이었습니다.배당금 증가: 6848 4 년 동안만 배당금을 지급해 왔으며 그 이후 지급액이 감소했습니다.배당 수익률 vs 시장RBC Bioscience 배당 수익률 vs 시장6848의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (6848)1.6%시장 하위 25% (TW)1.4%시장 상위 25% (TW)5.0%업계 평균 (Life Sciences)1.4%분석가 예측 (6848) (최대 3년)n/a주목할만한 배당금: 6848 의 배당금( 1.58% )은 TW 시장에서 배당금 지급자의 하위 25%( 1.42% )보다 높습니다.고배당: 6848 의 배당금( 1.58% )은 TW 시장에서 배당금 지급자의 상위 25%( 5% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 21.9% )이 낮기 때문에 6848 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 14.2% )이 낮기 때문에 6848 의 배당금 지급은 현금 흐름으로 완전히 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 14:37종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스RBC Bioscience Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • Sep 25Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 02 October 2025. Payment date: 31 October 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.7%).
Upcoming Dividend • Sep 12Upcoming dividend of NT$0.56 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 18 October 2024. Payout ratio is on the higher end at 75%, however this is supported by cash flows. Trailing yield: 5.6%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (1.2%).
Upcoming Dividend • Jul 29Upcoming dividend of NT$0.44 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 30 August 2024. Payout ratio is on the higher end at 89%, and the cash payout ratio is above 100%. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (1.3%).
Upcoming Dividend • Jul 06Upcoming dividend of NT$1.12 per share at 6.2% yieldEligible shareholders must have bought the stock before 13 July 2023. Payment date: 11 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 6.2%. Within top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.0%).
Reported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$1.65 (vs NT$1.51 in FY 2024)Full year 2025 results: EPS: NT$1.65 (up from NT$1.51 in FY 2024). Revenue: NT$219.7m (up 7.0% from FY 2024). Net income: NT$23.5m (up 9.2% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Apr 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 9.1% to NT$17.90. The fair value is estimated to be NT$14.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
공시 • Apr 01RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$218.6m market cap, or US$6.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Jan 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$212.8m market cap, or US$6.72m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Buy Or Sell Opportunity • Dec 16Now 21% overvaluedOver the last 90 days, the stock has fallen 7.6% to NT$17.00. The fair value is estimated to be NT$14.10, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
Buy Or Sell Opportunity • Nov 26Now 21% overvaluedOver the last 90 days, the stock has fallen 5.7% to NT$17.30. The fair value is estimated to be NT$14.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
Buy Or Sell Opportunity • Nov 11Now 21% overvaluedOver the last 90 days, the stock has fallen 2.0% to NT$17.55. The fair value is estimated to be NT$14.53, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
Upcoming Dividend • Sep 25Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 02 October 2025. Payment date: 31 October 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.7%).
공시 • Mar 31RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$260.2m market cap, or US$7.90m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Dec 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$254.3m market cap, or US$7.75m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.1% average weekly change).
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$267.3m market cap, or US$8.32m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.4% average weekly change).
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$22.70, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total returns to shareholders of 59% over the past year.
Upcoming Dividend • Sep 12Upcoming dividend of NT$0.56 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 18 October 2024. Payout ratio is on the higher end at 75%, however this is supported by cash flows. Trailing yield: 5.6%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (1.2%).
Upcoming Dividend • Jul 29Upcoming dividend of NT$0.44 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 30 August 2024. Payout ratio is on the higher end at 89%, and the cash payout ratio is above 100%. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (1.3%).
Reported Earnings • Apr 25Full year 2023 earnings released: EPS: NT$0.50 (vs NT$0.29 in FY 2022)Full year 2023 results: EPS: NT$0.50 (up from NT$0.29 in FY 2022). Revenue: NT$172.5m (flat on FY 2022). Net income: NT$6.43m (up 70% from FY 2022). Profit margin: 3.7% (up from 2.2% in FY 2022).
공시 • Apr 12RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024.
New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.3x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (NT$209.6m market cap, or US$6.63m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change).
Buy Or Sell Opportunity • Feb 20Now 23% undervaluedOver the last 90 days, the stock has risen 5.3% to NT$15.90. The fair value is estimated to be NT$20.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 4.8% to NT$15.25. The fair value is estimated to be NT$19.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Buying Opportunity • Jan 16Now 21% undervaluedOver the last 90 days, the stock is up 3.8%. The fair value is estimated to be NT$19.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Buying Opportunity • Nov 29Now 20% undervaluedOver the last 90 days, the stock is up 3.7%. The fair value is estimated to be NT$19.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Upcoming Dividend • Jul 06Upcoming dividend of NT$1.12 per share at 6.2% yieldEligible shareholders must have bought the stock before 13 July 2023. Payment date: 11 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 6.2%. Within top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.0%).
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$21.25, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 40% over the past year.
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 26%After last week's 26% share price gain to NT$17.75, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 49% over the past year.
Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$17.70, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total loss to shareholders of 43% over the past year.
Valuation Update With 7 Day Price Move • Apr 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$47.15, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 35x in the Life Sciences industry in Asia.